ABSTRACT Background: Polyunsaturated fatty acids can have beneficial effects on human immune cells, such as peripheral blood mononuclear cells (PBMCs). However, the mechanisms of action of polyunsaturated fatty acids on immune cells are still largely unknown. Objective: The objective was to examine the effects of supplementation with the polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on whole-genome PBMC gene expression profiles, in healthy Dutch elderly subjects participating in a double-blind trial, by using whole-genome transcriptomics analysis. Design: The subjects were randomly allocated to 1 of 3 groups: 1) consumption of 1.8 g EPA+DHA/d (n = 36), 2) consumption of 0.4 g EPA+DHA/d (n = 37), or 3) consumption of 4.0 g high-oleic acid sunflower oil (HOSF)/d (n = 38). All supplements were given in capsules. Before and after 26 wk of intervention, blood samples were collected. Microarray analysis was performed on PBMC RNA from 23 subjects who received 1.8 g EPA+DHA/d and 25 subjects who received HOSF capsules. Quantitative real-time polymerase chain reaction was performed in all 111 subjects. Results: A high EPA+DHA intake changed the expression of 1040 genes, whereas HOSF intake changed the expression of only 298 genes. EPA+DHA intake resulted in a decreased expression of genes involved in inflammatory-and atherogenic-related pathways, such as nuclear transcription factor jB signaling, eicosanoid synthesis, scavenger receptor activity, adipogenesis, and hypoxia signaling. Conclusion: These results are the first to show that intake of EPA+DHA for 26 wk can alter the gene expression profiles of PBMCs to a more antiinflammatory and antiatherogenic status. This trial was registered at clinicaltrials.gov as NCT00124852.
INTRODUCTION
The beneficial effects of long-chain n23 polyunsaturated fatty acids (PUFAs), such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), on inflammation (1) and cardiovascular diseases (2) are generally accepted. Immune cells, such as peripheral blood mononuclear cells (PBMCs), play a vital role in inflammation and the development of cardiovascular diseases. However, the cellular mechanisms of action of PUFAs on immune cells are not completely understood (3) . It is recognized that PUFAs can modulate cellular function through changes in gene expression, eg, via binding and subsequent activation of peroxisome proliferator-activated receptors (PPARs) (4) . Activation of these nuclear receptors is known to up-and downregulate the expression of genes involved in lipid metabolism and inflammation, respectively. Moreover, PUFAs such as DHA and EPA are stronger natural ligands for PPARs than are monounsaturated or saturated fatty acids (5) . We recently showed that PPARa, one of the subtypes of PPARs, has a functional role in human PBMCs (6) .
Various long-term intervention trials have been performed to elucidate the mode of action of PUFAs, such as EPA and DHA, in human immune cells (7); however, most of these trials only studied the ex vivo immunological function of these cells. To obtain a more comprehensive overview of the processes that are modulated by EPA and DHA in immune cells such as PBMCs, in vivo, a whole-genome transcriptomic analysis would be more valuable. In a previous study we showed that the effects of endogenous fatty acids on human PBMCs can be elucidated by using a genomics approach (8) . However, the effects of the longterm intake of fatty acids on PBMC gene expression profiles have not yet been studied. Therefore, we examined the effects of EPA+DHA supplementation for 26 wk on whole-genome PBMC gene expression profiles in a Dutch elderly population and compared the effects with those of control supplementation with high-oleic acid sunflower oil (HOSF).
SUBJECTS AND METHODS

Subjects
Three hundred fifty-one subjects aged 65 y were screened, of whom 189 were men and 162 were women. Three hundred two subjects (167 men and 135 women) were included in the study, and detailed baseline characteristics of these participants were described elsewhere (9) . From these participants, 111 subjects were randomly included in the present study ( Figure 1) . The participants were recruited according to the following exclusion criteria: current or recent (,4 wk) use of fish-oil supplements or intake of fish .4 times/wk or .800 mg EPA+DHA/d from fish as estimated by using a fish-consumption questionnaire, serious liver disease, consumption of .4 glasses of alcoholcontaining beverages per day, unable to participate as judged by the responsible medical physician, allergy to fish or fish oil, swallowing problems, or participation in another clinical trial ,2 mo before the start of the trial or at the same time. Cognitive exclusion criteria were also used, as described elsewhere (9) . Additionally, compliance with capsule use during a 2-wk placebo run-in period had to be 80% on the basis of self-report. All subjects gave written informed consent to participate in the study, and the study protocol was approved by the Medical Ethical Committee of Wageningen University, Wageningen, Netherlands.
Study design
The subjects were randomly allocated to receive a daily dose of fish oil containing either a low dose of EPA+DHA (0.4 g; n = 36), a high dose of EPA+DHA (1.8 g; n = 37), or HOSF (n = 38) for a period of 26 wk (Lipid Nutrition/Loders Croklaan, Wormerveer, Netherlands) (Figure 1) . The oils were administered in 6 soft gelatin capsules daily, each of which contained 900 mg oil and 2.7 mg tocopherol as antioxidant (Banner Pharmacaps Europe BV, Tilburg, Netherlands). The fatty acid composition of the capsules was measured in 20 capsules taken at regular times during the study.
Blood sampling and PBMC isolation
Fasting venous blood samples were collected at baseline and after 26 wk of intervention. A blood sample for measurement of n23 PUFAs was collected into 10-mL EDTA-Vacutainers (Becton Dickinson, Breda, Netherlands), immediately placed on ice, centrifuged at 2000 · g at a temperature of 4°C, and then stored at 280°C until laboratory analyses. n23 PUFAs in plasma cholesteryl esters were measured as described previously (10) . Plasma free fatty acids and triglycerides were measured by gasliquid chromatography, and C-reactive protein (CRP) concentrations were determined from measurements of high-sensitivity CRP (hsCRP). For PBMC isolation, 4 mL blood was collected into Becton Dickinson Vacutainer Cell Preparation Tubes with sodium citrate. PBMCs were isolated immediately after blood collection according to the manufacturer's instructions.
Total RNA isolation
PBMC RNA was isolated from all PBMC samples by using a Qiagen RNeasy Micro kit (Qiagen, Venlo, Netherlands). The RNA yield was quantified with a Nanodrop ND 1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE), and integrity was measured with an Agilent 2100 Bioanalyzer with RNA 6000 Nano chips (Agilent Technologies, South Queensferry, United Kingdom).
Microarray processing
PBMC samples from 77 subjects yielded enough RNA to perform microarray analysis. Deblinding showed that 25 subjects were in the high EPA+DHA group, 26 in the low EPA+DHA group, and 26 in the HOSF group. Microarray analysis was performed on baseline samples and on samples after 26 wk of intervention in the high EPA+DHA group and the HOSF group. Total RNA from the PBMCs of these 51 subjects was labeled by using a one-cycle cDNA labeling kit (MessageAmp II-Biotin Enhanced Kit; Ambion Inc, Nieuwekerk a/d IJssel, Netherlands) and hybridized to human whole-genome NuGO GeneChip arrays encoding 17,699 genes, designed by the European Nutrigenomics Organization and manufactured by Affymetrix (Affymetrix Inc, Santa Clara, CA). Sample labeling, hybridization to chips, and image scanning were performed according to the manufacturer's GeneChip Expression Analysis Technical Manual (Affymetrix).
Microarray analysis
Microarrays from 3 subjects, 2 from the high EPA+DHA group, and 1 from the HOSF group were excluded because they did not fulfill our quality-control criteria. Microarrays were analyzed by using the reorganized oligonucleotide probes as described by Dai et al (11) . Expression values were calculated by using the Robust Multichip Average method. The Robust Multichip Average signal value estimates are based on a robust average of background-corrected perfect match intensities, and normalization was performed by using quantile normalization (12) . Only genes with normalized signals .20 on 10 arrays were defined as "expressed" and selected for further analysis. Genes were defined as "changed" when comparison of the normalized signal intensities showed a false discovery rate Q value (13) ,0.05 in a 2-tailed paired t test with Bayesian correction (Limma) (14) . Pathway analysis was performed by using GenMAPP 2.1 (www.genmapp.org), Ingenuity Pathway Analysis 5.5 (www.ingenuity.com), and Gene Set Enrichment Analysis 2.0.1 (http://www.broad.mit.edu/gsea/) (15) . Pathways were defined as significantly changed when P , 0.05 (Ingenuity Pathway Analysis and Gene Set Enrichment Analysis) or the z score was .1 (GenMAPP).
cDNA synthesis and real-time quantitative polymerase chain reaction RNA from all subjects was reverse transcribed with use of a cDNA synthesis kit (Promega, Leiden, Netherlands). Standard quantitative real-time polymerase chain reaction (Q-PCR) was performed with use of Platinum Taq DNA polymerase and SYBR Green on an iCycler PCR machine (Bio-Rad Laboratories BV, Veenendaal, Netherlands) and duplicated at least twice. Primer sequences used in the PCRs were chosen based on the sequences available in PRIMERBANK (http://pga.mgh.harvard.edu/ primerbank/index.html). Q-PCR data were normalized by measuring cycle threshold ratios between candidate genes and a housekeeping gene, human ribosomal protein LP0.
Statistical analysis
Differences between end and baseline values of plasma metabolites and Q-PCR results were tested by using a paired t test. Statistical significance was accepted at P , 0.05. Differences between groups were tested by using a 2-factor ANOVA with a Tukey honestly significant difference post hoc test to correct for multiple testing of 3 treatment groups with SPPS software (version 12.0.1; SPSS Inc, Chicago, IL). Statistical significance was accepted at P , 0.05.
RESULTS
Subject characteristics
Of the 302 participants enrolled in the study, blood samples were randomly collected from 111 healthy men and woman aged 66-80 y. A subset of these samples was used to perform microarray hybridizations ( Figure 1 ). The baseline characteristics of the participants are shown in Table 1 . No significant differences were observed between the intervention groups, both for the whole group and for the subgroup in which the microarrays were performed. To confirm the amount of the various fatty acids the participants consumed daily, the fatty acid composition of the capsules was measured ( Table 2 ). The high-dose EPA+DHA supplement provided 1093 6 17 mg EPA (mean 6 SD) and 847 6 23 mg DHA daily, and the low-dose EPA+DHA supplement provided 226 6 3 mg EPA and 176 6 4 mg of DHA daily.
Plasma measurements
To check individual compliance with intake, the plasma fatty acid composition was determined in cholesteryl esters at baseline and after 26 wk ( 
Microarray analysis
Microarray hybridization was performed on PBMC RNA that was collected at baseline and after 26 wk of supplementation from 25 subjects in the high-dose EPA+DHA group and from 26 subjects in the HOSF group. Two arrays in the high-dose EPA+DHA group and one array in the HOSF group did not pass the quality-control criteria. Changes in gene expression were determined by comparing the microarray results of the samples after 26 wk of intervention with the baseline samples, for both intervention groups. From the 17,699 genes present on the microarray, 12,256 genes were defined as expressed in PBMCs ( Figure 3) . Consumption of 1.8 g EPA+DHA/d for 26 wk resulted in gene expression changes of 1040 genes, whereas consumption of the HOSF capsules resulted in expression changes of 298 genes ( Figure 3 ). Of these genes, 140 were overlapping between the groups, which resulted in 900 uniquely changed genes in the EPA+DHA group. Except for one gene, the direction of change of the overlapping genes was the same in the EPA+DHA and the HOSF groups (data not shown).
Pathway analysis
To determine the role of the genes that changed with EPA+DHA supplementation, we performed pathway analysis. GenMAPP analysis showed that supplementation with a high dose of EPA+DHA for 26 wk significantly decreased the expression of genes involved in inflammatory pathways, such as eicosanoid synthesis, interleukin signaling, and MAP kinase signaling ( Figure 4) . In addition, a decreased expression of genes involved in pathways related to atherosclerotic processes, such as cell adhesion, scavenger receptor activity, and adipogenesis, was observed. Ingenuity Pathway Analysis and Gene Set Enrichment Analysis showed similar decreases in inflammatory signaling pathways, such as eicosanoid metabolism and interleukin-6 and MAP kinase signaling, with additional signaling routes such as nuclear transcription factor jB (NF-jB) and Toll-like receptor signaling. These programs also showed a decrease in oxidative stress, cell adhesion, PPAR signaling, LXR/RXR (liver X receptor/retinoid X receptor) activation, and hypoxia signaling in the cardiovascular system, which includes hypoxia initiation factor 1a signaling (data not shown).
In addition to the genes present in the above-described pathways, several other genes involved in similar processes, but not present in the pathways, were down-regulated ( Figure 5) . A list of inflammatory-related genes, such as NF-jB target genes, oncostatin M (OSM), Ig-like receptors, and interleukin receptors, that were down-regulated in the high-dose EPA+DHA group are shown in Figure 5 . Several plaque stability-related metallopeptidases, which also decreased with EPA+DHA supplementation, are also listed in Figure 5 .
Interestingly, pathway analysis of genes changed in the HOSF group also showed down-regulation of genes involved in inflammation and cell adhesion (Figure 4) . However, the expression of fewer genes changed with HOSF intake; consequently, fewer genes were observed in the changed pathways. Additionally, we studied the expression changes of previously described PPARa target genes in PBMCs (6) and observed that 14 of these 106 PPAR response element-containing PPARa target genes were down-regulated, and 2 were up-regulated ( Table 3) .
To determine whether a low dose of 0.4 g EPA+DHA/d can induce gene expression changes similar to those seen with a high dose of 1.8 g EPA+DHA/d, 6 genes selected from several changed pathways were analyzed with Q-PCR in the whole study population of 111 individuals ( Figure 6 ). Q-PCR of CD36, PDK4, LTA4H, ADFP, CD14, and HIF1a showed that consumption of 0.4 g EPA+DHA/d for 26 wk also resulted in a down-regulation of the expression of these genes and that the effects were intermediate between the effect of the high-dose EPA+DHA group and the HOSF group. These data also confirm the microarray results, as reflected by the same direction of gene expression changes.
DISCUSSION
In this study we assessed changes in PBMC gene expression profiles after fish-oil or control-oil supplementation in a 26-wk double-blind and randomized intervention trial in an elderly population. Supplementation with 1.8 g EPA+DHA/d, the equivalent of the consumption of 10 portions of fatty fish weekly, resulted in antiinflammatory-and antiatherogenic-like changes in PBMC gene expression profiles. In addition, supplementation with 0.4 g EPA+DHA/d, the equivalent of the consumption of 2 portions of fatty fish weekly, which approaches the average intake (17) (18) (19) . However, the effect of fish-oil supplementation on whole-genome gene expression profiles in human PBMCs has not been examined before. The antiinflammatory-like gene expression profile observed in the present study is mainly characterized by a decreased expression of inflammatory genes, including several NF-jB target genes, proinflammatory cytokines, and genes involved in eicosanoid synthesis. Several other intervention studies in healthy subjects with varying doses of n23 fatty acids showed a reduction in cytokine formation after ex vivo stimulation of mononuclear cells (20, 21) . The decrease in eicosanoid formation we observed was characterized by a downregulation in the gene expression of enzymes involved in eicosanoid synthesis, such as LTA4H and ALOX-5. It is known that n23 PUFA supplementation can result in a decrease in proinflammatory arachidonic acid-derived eicosanoids (1). For example, various ex vivo stimulation studies with inflammatory cells in healthy volunteers showed that supplementation with fish oil or DHA for 4 to 17 wk resulted in a decreased production of eicosanoids (1) . In addition, intake of n23 fatty acids for 6 wk reduced the urinary excretion of leukotriene E4 (22) . Hence, our observations on PBMC gene expression are in line with previously observed n23 PUFA-induced effects after ex vivo stimulation. The subjects who consumed the HOSF capsules showed a similar, albeit less pronounced, effect on some of the inflammatory pathways changed by EPA+DHA supplementation. The overlapping genes were almost all changed in the same Brackets indicate differences between groups as determined with a 2-factor ANOVA with Tukey honestly significant difference correction (*P , 0.05, **P , 0.01). Differences within groups were determined with a paired t test (**P , 0.01). Note that the y axes of the graphs differ. The pathways included had a z score of 1 and had 2 genes changed. MAPKKK, mitogenactivated protein kinase kinase kinase; KEGG, Kyoto Encyclopedia of Genes and Genomes; HSP, heat shock protein; GPCRs, G protein-coupled receptors; EGFR1, epidermal growth factor receptor 1; TNF-alpha-NF-jB, tumor necrosis factor-a-nuclear transcription factor-jB; Krebs TCA cycle, Krebs tricarboxylic acid cycle; NetPath (http://www.netpath.org/); PharmGKB, pharmacogenomics knowledge base (http://www.pharmgkb.org/); Biocarta (http:// www.biocarta.com/). FIGURE 5. Genes changed after eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) supplementation in various functional groups that were overrepresented by the pathway analyses software programs GenMAPP (www.genmapp. org), Ingenuity Pathway Analysis (www.ingenuity.com), and Gene Set Enrichment Analysis (http://www.broad.mit.edu/ gsea/), supplemented with changed genes also related to these processes. Asterisks indicate that the genes appear in multiple functional groups. FC, fold change; NF-jB, nuclear transcription factor jB; ROS, reactive oxygen species; PPAR, peroxisome proliferator-activated receptors; HIF, hypoxiainduced factor. direction, which suggested that some of the effects on inflammation, although clearly less apparent, were comparable with the EPA+DHA intervention. Beneficial effects of MUFAs on inflammation have been reported, but only limited data are available (23) . The antiatherogenic gene expression profile that we observed in this study after EPA+DHA intake is characterized by a reduced expression of genes that play a role in several processes known to be involved in atherosclerotic plaque formation. PBMC subpopulations are involved in these processes, which include adhesion, infiltration, and subsequent foam cell . Mean (6SEM) changes in the expression of a selection of genes determined by quantitative real-time polymerase chain reaction changes after supplementation with a high dose of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) (n = 36), a low dose of EPA+DHA (n = 37), or high-oleic acid sunflower oil (HOSF; n = 38). CD36, CD36 antigen; PDK4, pyruvate dehydrogenase kinase 4; LTA4H, leukotriene A4 hydrolase; ADFP, adipose differentiation related protein; CD14, CD14 antigen; HIF1a, hypoxia-induced factor 1a. Brackets indicate differences between groups as determined with a 2-factor ANOVA with Tukey honestly significant difference correction (*P , 0.05, **P , 0.01). Differences within groups were determined with a paired t test (**P , 0.01, *P , 0.05).
formation (24) . We found an EPA+DHA-induced decrease in the expression of genes involved in integrin-mediated cell adhesion and foam cell formation. An n23 PUFA-induced decrease in the expression of monocyte and macrophage adhesion molecules was previously reported, but only in animal and in vitro studies (25, 26) . A reduction in foam cell formation is characterized by a lower gene expression of the scavenger receptor CD36 and the LDL receptors and a decrease in the expression of genes involved in lipid accumulation, such as adipose differentiationrelated protein. It has been shown that incubation of monocytes with n23 PUFAs in vitro can reduce CD36 mRNA and protein expression (27) . Incubation of macrophages with PUFAenriched chylomicron remnant-like particles in vitro resulted in reduced lipid accumulation in these cells (28) . The reduced gene expression of scavenger receptors and of adipose differentiationrelated protein that we observed in our in vivo study are in line with these in vitro data and might imply that the monocytes present within the PBMCs are less prone to differentiate into foam cells after 26 wk of EPA+DHA supplementation. Besides the abovementioned changes in foam cell formation, we also observed decreases in genes such as matrix metalloproteinases and disintegrin metalloproteinases, which are related to plaque stability, a process that normally occurs after infiltration and foam cell formation. These genes are known to destabilize atherosclerotic plaques, which can result in plaque rupture (29) . Also, the hypoxia inducible factor 1a gene (HIF1a) and its main target gene, the vascular endothelial growth factor gene (VEGF), were down-regulated (30) . Both genes are known to regulate atherosclerotic plaque angiogenesis, which destabilizes and progresses the lesion. Plaque stability has been found to increase after n23 PUFA supplementation (31) .
The high-dose EPA+DHA intake in our study also increased the expression of nitric oxide synthase 3, which plays a role in the protection of the vessel wall from atherosclerosis (32) . Increased expression of nitric oxide synthase 3 in murine macrophages and in vitro in human vascular wall cells after supplementation or incubation with EPA+DHA has been shown before (33) (34) (35) . Importantly, all studies described above illustrate short-term in vitro experiments or animal studies, whereas we observed our effects in healthy humans after 26 wk of n23 PUFA intake. Because we observed changes in PBMC gene expression profiles with EPA+DHA supplementation that indicate antiinflammatoryand antiatherogenic-like modifications, we speculate that EPA+DHA supplementation might improve the preatherosclerotic condition in elderly people.
An interesting point to discuss is whether the changes in gene transcription profiles were due to a direct effect of EPA+DHA on mononuclear cells or whether the changes reflected the response of PBMCs to EPA+DHA-induced systemic adaptations in the body. A nice illustration in this respect is the unexpected finding of down-regulation of PPARa target genes after EPA+DHA supplementation. On the basis of mice and in vitro studies, in which a more pronounced expression of PPAR target genes was observed on EPA and DHA intakes than on monounsaturated fatty acid intake (5), we expected an increase in PPARa target genes on EPA+DHA supplementation instead of the observed decreases. A possible explanation for these unexpected findings may lie in systemic long-term adaptations via effects of EPA+ DHA on gut or liver, resulting in reduced plasma FFA and triglyceride concentrations. The observed down-regulation of PPAR target genes might have been caused by these reduced plasma FFA and TG concentrations. Hence, PBMC gene expression profiles could also be viewed as a reflection of the physiologic state of subjects, as we showed previously (8) .
Microarrays were performed only in the subjects who consumed the high dose of EPA+DHA, reflecting a relatively high consumption of 10 portions of fatty fish weekly. However, Q-PCR results showed that a lower dose, representing the intake of 2 portions of fatty fish weekly, resulted in lower, but similar, gene expression changes. This finding suggests that lower amounts of fish intake may have similar effects on PBMC gene expression profiles, especially when taken for a longer period. In addition, our study population consisted of elderly individuals, which likely express a slightly more proinflammatory and proatherosclerotic gene expression profile, because aging is associated with chronic, low-grade increased inflammatory activity (36) . Therefore, the observed results cannot be generalized to the whole population. However, it does make the studied population suitable to detect nutrition-induced changes on transcriptional profiles, even when plasma CRP concentrations are not changed yet. It has been reported that the effects of PUFA supplementation are mainly detectable when CRP is already elevated at baseline (37-39), which was not the case in our population. Moreover, CRP is mainly produced by the liver, whereas a down-regulation of inflammatory markers was observed on PBMC transcriptomes. Because of the limited amount of PBMC material, confirmation on protein level could not be determined in PBMCs. A recent transcriptomics study in PBMCs showed that weight loss in obese men led to a similar reduction in the expression of inflammatory genes as observed in our study (40) . Interestingly, the effects in our study were obtained in lean subjects, merely by supplementation with 1.8 g EPA+DHA and even with 0.4 g EPA+DHA/d. This emphasizes the potential of PBMC gene expression profiling to determine the effects of nutrition on human health status. In conclusion, this study showed that the intake of the n23 PUFAs EPA and DHA for 26 wk alters the gene expression profiles of PBMCs in the direction of a more antiinflammatory-and antiatherogenic-like profile. Moreover, this nutrigenomics study showed that PBMC profiling cannot only reflect pathological conditions, but can also reflect metabolic changes due to longterm nutritional adaptations in healthy humans.
